The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed New Long Term Incentive Plan

11 Oct 2010 16:00

RNS Number : 2047U
PuriCore Plc
11 October 2010
 



PuriCore plc  

Proposed New Long Term Incentive Plan and Proposed Amendment to the Existing Option Plan and Notice of General Meeting

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 11 October 2010 - PuriCore plc (LSE: PURI) ("PuriCore" or the "Company"), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that it is proposing a new Long Term Incentive Plan ("LTIP") and an amendment to the Company's Executive Omnibus Incentive Plan (the "Option Plan").

 

A circular is expected to be posted today to Shareholders by the Company that contains details of the LTIP and the associated proposed change to the Option Plan (the "Circular"). The Directors are seeking approval of the LTIP and the amendment to the Option Plan at a General Meeting to be held at 9.00 a.m. at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD on 29 October 2010.

 

PuriCore Value Sharing Plan (LTIP)

The LTIP allows the creation of an award pool of 15% of the amount by which the market capitalisation of the Company exceeds £35 million on 30 September 2012. This award pool will be allocated amongst the participants at a pre-determined rate and is intended to be satisfied through a combination of new ordinary shares and cash. To implement the LTIP, the Option Plan is proposed to be amended to exclude the issue of any share awards under the LTIP from the Option Plan dilution limit.

 

PuriCore will realise short-term cash savings from the implementation of the LTIP as some participants are accepting reductions in cash-based compensation-for the term of the LTIP-in exchange for participation in the LTIP. These reductions include foregoing employer retirement plan contributions and waiving rights to the annual bonus scheme, for those participants who are entitled to these benefits, and certain participants taking an approximate 17% reduction in basic salary. Further, all participants must waive their rights to existing share option grants, whether vested or unvested.

 

A summary of the LTIP and a summary of the proposed amendment to the Option Plan is set out in the Circular.

 

Background to the PuriCore Value Sharing Plan

The Remuneration Committee of the Board of Directors (the "Remuneration Committee") believes the LTIP is an appropriate tool to motivate the participants to achieve the Company's sales growth and profitability goals, and to deliver significant value to shareholders in terms of market capitalisation increase. The Remuneration Committee is confident that the senior executive team charged with delivering the Company's goals is focused and that the strategies being implemented should allow the Company to meet its goals on an accelerated basis. Aligning the senior executive remuneration strategy with the Company's business goals and with the interests of shareholders is critical. The Remuneration Committee believes the LTIP does this in the following ways:

 

·; incentivises the participants to focus on strategies and tactics with a common goal of creating shareholder wealth by increasing market capitalisation;

 

·; establishes a challenging market capitalisation hurdle of £35 million (compared with the current market capitalisation of approximately £13 million) below which participants receive no pay-out;

 

·; provides a short-term (24-month) period for delivering on the Company's goals; and

 

·; offers flexibility in the type of senior executive remuneration (shares or cash), which the Remuneration Committee can utilise based on the financial and cash position of the Company at the time of the award.

 

A copy of the Circular and related form of proxy have been submitted to the National Storage Mechanism and will shortly be available for inspection. The Notice of General Meeting will shortly be available on the Company's website.

 

Enquiries:

 

Financial Dynamics

PuriCore

Susan Quigley

Chris Wightman

Ben Brewerton

Executive Chairman

+44 (0) 20 7831 3113

+44 (0) 20 7290 3440

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALEFFSEEFFF
Date   Source Headline
18th Aug 20167:00 amRNSBlock listing Interim Review
17th Aug 20167:00 amRNSPuriCore Receives Two U.S. Patents
16th Jun 201611:39 amRNSResult of AGM
9th Jun 20167:00 amRNSCompletion of Pre-IND Meeting with FDA on PR022
27th May 20167:00 amRNSResolution reached with EPA
14th Apr 20167:00 amRNSAppointment of Dr. Christian Peters as CMO
31st Mar 20167:00 amRNSNotice of AGM
29th Mar 20163:11 pmRNSDirector Dealing
29th Mar 20167:00 amRNSGrant of Options
24th Mar 20163:22 pmRNSAnnual Financial Report
24th Mar 20167:00 amRNSFinal Results
1st Mar 20167:00 amRNSAppointment of Dr Simba Gill to the Board
19th Feb 20169:30 amRNSBlocklisting Interim Review
8th Feb 20167:00 amRNSStrategic Review and Trading Update
4th Jan 201610:21 amRNSHolding(s) in Company
21st Dec 20158:55 amRNSHolding(s) in Company
14th Oct 20155:13 pmRNSDirector Dealing
30th Sep 20156:08 pmRNSHolding(s) in Company
28th Sep 20157:00 amRNSDirector Dealings
23rd Sep 20157:00 amRNSHalf Yearly Report
19th Aug 20158:33 amRNSBlocklisting Interim Review
1st Jul 20157:00 amRNSChange of Registered Office
19th Jun 20157:00 amRNSBoard Changes
18th Jun 201511:00 amRNSResult of AGM
9th Jun 20155:02 pmRNSGrant of Options
19th May 20157:00 amRNSAppointment of Alex Martin as CEO
2nd Apr 20157:00 amRNSDirector Dealing
31st Mar 20157:00 amRNSFinal Results
30th Mar 201512:22 pmRNSHolding(s) in Company
19th Mar 20157:00 amRNSSigns Major Supermarket Deal
24th Feb 20157:00 amRNSTrading Update
17th Feb 20158:24 amRNSBlocklisting Interim Review
9th Jan 20157:00 amRNSHolding(s) in Company
23rd Dec 20148:00 amRNSCancellation - PuriCore Plc
23rd Dec 20147:00 amRNSPuricore commences trading on AIM
25th Nov 20147:00 amRNSStrategic and Operational Review Update
24th Nov 20142:03 pmRNSResult of General Meeting
7th Nov 20147:00 amRNSProposed listing changes and notice of GM
5th Nov 20147:00 amRNSPuriCore granted two U.S. patents
31st Oct 20147:00 amRNSInterim Management Statement
14th Oct 20147:00 amRNSPlanned Directorate Changes
12th Aug 201411:49 amRNSDirector Dealing
11th Aug 20147:00 amRNSBlocklisting Interim Review
8th Aug 20147:00 amRNSHalf Yearly Report
31st Jul 20141:51 pmRNSNotice of Results
11th Jul 20147:00 amRNSTrading Update and Strategic Review
1st Jul 20147:00 amRNSCompletes Sale of UK Endoscopy Business
23rd Jun 20147:00 amRNSBoard Changes
20th Jun 201410:59 amRNSResult of General Meeting
19th Jun 201411:49 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.